Interpace Biosciences, Inc. (IDXG)
Oxford Ledge is still expanding full research coverage of IDXG. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
The company provides molecular diagnostic tests for cancer evaluation, primarily focused on thyroid cancer testing after discontinuing a pancreatic cancer test.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-07-07
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- 10-K/A Amended annual report 2026-04-30
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-04-01
Source: SEC EDGAR.
Annual results
5 years of annual figures for IDXG, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $38.7M | $24.6M | $0.89 |
| 2024 | $46.9M | $6.7M | $0.40 |
| 2023 | $40.0M | $2.0M | $0.45 |
| 2022 | $31.8M | -$22.0M | -$5.18 |
| 2021 | $33.1M | -$14.9M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for IDXG. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open IDXG in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.